The ACCELERATE Trial

Recommendations

Info

Background • Despite widespread use of statins, many patients continue to experience cardiovascular events. • Considerable efforts have focused on the protective effects of HDL as a potentially useful therapeutic approach. • Animal and genetic studies suggest that CETP deficiency is cardioprotective. However, prior trials demonstrated adverse outcomes with torcetrapib and futility with dalcetrapib • CETP inhibitors lacking the toxicity of torcetrapib have been considered a promising approach to addressing residual risk. • Evacetrapib is a potent CETP inhibitor with favorable effects on HDL-C, LDL-C, Lp(a) and cholesterol efflux in phase 2.
<strong>ACCELERATE</strong> <strong>Trial</strong> Design 12,092 patients at high vascular risk, defined as: – ACS within 30-365 days – Diabetes with coronary disease – Peripheral arterial disease – Cerebrovascular disease 1:1 randomization Evacetrapib 130 mg Placebo • Event driven - Primary endpoint in 1670 patients (CV death, MI, stroke, coronary revascularization or hosp. for unstable angina) • Minimum of 700 patients with hard events (CV death, MI or stroke), minimum of 1.5 years of follow-up per patient • 84% power to detect a 13.5% reduction in the primary endpoint
Page 1 and 2: The ACCELERATE Trial Impact of the
Page 3: Role of Cholesteryl Ester Transfer
Page 7 and 8: Baseline Clinical Characteristics P
Page 9 and 10: Adherence and Retention Placebo (n=
Page 11 and 12: Percent Change in LDL-C Levels Duri
Page 13 and 14: Secondary Efficacy Endpoints Placeb
Page 15 and 16: Systolic Blood Pressure During the
Page 17: ACCELERATE Data Sharing Initiative

The ACCELERATE Trial

Create successful ePaper yourself

Delete template?

Save as template?